

ADMINISTRATIVE POLICY STATEMENT


Ohio Medicaid

Policy Name & Number	Date Effective
Pharmacogenomics-CYP Gene Testing-OH MCD-AD-1342	04/01/2024
Policy Type	
ADMINISTRATIVE	

standards, and published MCO clinical policy guidelines. Medically necessary services include, but are not limited to, those health care services or supplies that are proper and necessary for the diagnosis or treatment of disease, illness, or injury and without which the patient can be expected to suffer prolonged, increased or new morbidity, impairment of function, dysfunction of a body organ or part, or significant pain and discomfort. These services meet the standards of good medical practice in the local area, are the lowest cost alternative, and are not provided mainly for the convenience of the member or provider. Medically necessary services also include those services defined in any Evidence of Coverage documents, Medical Policy Statements,



13. Clinical utility evaluation: pharmacogenetic and pharmacogenomic testing to improve outcomes related to opioid use disorder. Hayes; 2020. Updated June 30, 2023. Accessed January 23, 2024. www.evidence.hayesinc.com
14. Clinical utility evaluation: pharmacogenomic testing for attention-deficit/hyperactivity disorder. Hayes; 2022. Updated March 31, 2023. Accessed January 23, 2024. www.evidence.hayesinc.com
15. Clinical utility evaluation: pharmacogenomic testing of selected mental health conditions. Hayes; 2021. Updated December 1, 2023. Accessed January 23, 2024. www.evidence.hayesinc.com
16. Clopidogrel pharmacogenetics-CYP2C19 gene: A-0631. MCG. 27th ed. Updated September 21, 2023. Accessed January 23, 2024. www.careweb.careguidelines.com
17. Deoxyribonucleic acid (DNA) fact sheet. National Human Genome Research Institute. Updated August 24, 2020. Accessed January 23, 2024. www.genome.gov
18. Hefti E, Blanco JG. Documenting pharmacogenomic testing with CPT codes. *J AHIMA*. 2016;87(1):56-59. Accessed January 23, 2024. www.pubmed.ncbi.nih.gov
19. Hicks JK, Bishop JR, Sangkuhl K, et al.; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. *Clin Pharmacol Ther*. 2015;98(2):127-134. doi:10.1002/cpt.147
20. Hippman C, Nislow C. Pharmacogenomic testing: clinical evidence and implementation challenges. *J Pers Med*. 2019;9(3):40. doi:10.3390/jpm9030040
21. Hyperhomocysteinemia: A-0629. MCG. 27th ed. Updated September 21, 2023. Accessed January 23, 2024. www.careweb.careguidelines.com
22. Kohlmann W, Slavotinek A. Genetic testing. UpToDate. Updated October 7, 2022. Accessed January 23, 2024. www.uptodate.com
23. Laboratory Requirements, 42 C.F.R. § 493 (2024).
24. Laboratory Services, OHIO ADMIN. CODE 5160-11-11 (2021).
25. List of cleared or approved companion diagnostic devices (in vitro and imaging tools). Food and Drug Administration. Updated December 21, 2023. Accessed January 23, 2024. www.fda.gov
26. Managed Care: Provider Network and Contracting Requirements. OHIO ADMIN. CODE 5160-26-05 (2022).
27. Medical code brief: 0345U-PL 792 reW* nBT/F1 11.04 Tf1 0 0 1 -0.0182 Tc[23.])JTJETQq0.0000091



31. *MolDx: Pharmacogenomics Testing*. Centers for Medicaid and Medicare Services; 2020. LCD ID L38394. Updated August 24, 2023. Accessed January 23, 2024. www.cms.gov
32. *MolDx: Repeat Germline Testing*. Centers for Medicaid and Medicare Services; 2020. LCD ID L38288. Revised December 7, 2023. Accessed January 23, 2024. www.cms.gov
33. Molecular test assessment: GeneSight Psychotropic (Assurex Health Inc./Myriad Neuroscience). Hayes; 2021. Updated November 13, 2023. Accessed January 23, 2024. www.evidence.hayesinc.com
34. National Cancer Institute (NCI). NCI Dictionary of Genetics Terms. National Institute of Health. Accessed January 23, 2024. www.cancer.gov
35. National Center for Biotechnology Information. Genetic testing registry. National Library of Medicine. Accessed January 23, 2024. www.ncbi.nlm.nih.gov
36. *National Correct Coding Initiative Policy Manual For Medicaid Services*. Centers for Medicaid and Medicare Services. Updated January 1, 2024. Accessed January 23, 2024. www.medicaid.gov
37. Opioid pharmacogenetics-CYP450 polymorphisms and OPRM1 gene: A-0992. MCG. 27th ed. Updated September 21, 2023. Accessed January 23, 2024. www.careweb.careguidelines.com
38. Pharmacogenetic testing. American Academy of Child and Adolescent Psychiatry. Updated December 2019. Accessed January 23, 2024

The ADMINISTRATIVE Policy Statement detailed above has received due consideration as defined in the ADMINISTRATIVE Policy Statement Policy and is approved.

